Amsterdam, the Netherlands, November 16, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces that its portfolio company Xeltis has raised a substantial new round. The clinical-stage medical device company pioneering a restorative approach in heart valve therapy, announced the completion of an oversubscribed €45 million ($52 million) Series C financing. The funding round was led by a global strategic investor with participation from venture capital fund Ysios Capital and a number of large private investors. Existing institutional investors (LSP, Kurma Partners and VI Partners) and private investors also participated in the financing. For more information, please visit www.xeltis.com.
The press release of Xeltis related to this transaction can be found here.
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
Contact:
Clemens van Blitterswijk, PhD
Partner LSP
+31 20 6645500